You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

67 Results
Guidelines and Advice
Status: Current
ID: GL-C50-29
Mar 2012
Cancer facts
Jul 2012
Cancer facts
Mar 2012
Guidelines and Advice
Status: Current
Dec 2012
Guidelines and Advice
Status: Education and Information
Dec 2012
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Updated
Mar 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Drug
Other Name(s): Jakavi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Zejula
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Sylvant®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025

Pages